logo

For the Inventor, By the Inventor

Cologne, Germany

Dorian Schönfeld

This inventor holds 6 USPTO granted patents and 1 EPO patent. Top assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dorian Schönfeld. Retrieved from https://idiyas.com/inventor/dorian-schönfeld

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 83.3

 

Average Co-Inventor Count = 13.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Köln, DE (2020)
  • Cologne, DE (2021 - 2024)

Company Filing History:

goldMedal2 out of 12,268 
 
Bayer Aktiengesellschaft
 patents
silverMedal2 out of 387 
 
Bayer Pharma Aktiengesellschaft
 patents
bronzeMedal2 out of 168 
 
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
 patents

Years Active: 2020-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents
1. 12384843 - Anti-semaphorin 3A antibodies (2025-08-12),
2. 12173068 - Anti-sema3a antibodies and uses thereof (2024-12-24),
3. 11866495 - Anti-CEACAM6 antibodies and uses thereof (2024-01-09),
4. 11773164 - Anti-CEACAM6 antibodies and uses thereof (2023-10-03),
5. 11071788 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies (2021-07-27),
6. 10584167 - Anti-CEACAM6 antibodies and uses thereof (2020-03-10),

Title: Dorian Schönfeld: Innovator in Antibody Research

Introduction

Dorian Schönfeld is a prominent inventor based in Cologne, Germany. He has made significant contributions to the field of antibody research, particularly focusing on Semaphorin 3A. With a total of 6 patents to his name, Schönfeld's work has the potential to impact various therapeutic applications.

Latest Patents

Schönfeld's latest patents include innovative developments in anti-Semaphorin 3A antibodies. One patent discloses an isolated antibody or antigen-binding fragment that specifically binds to human Semaphorin 3A (Sema3A). This patent also covers an antibody conjugate and a pharmaceutical composition that incorporates this isolated antibody. Another patent details an isolated antibody that binds to human Sema3A with a high degree of specificity and potency, demonstrating its effectiveness in various in vitro assays.

Career Highlights

Throughout his career, Dorian Schönfeld has worked with notable organizations such as the Deutsches Krebsforschungszentrum and Bayer Pharma Aktiengesellschaft. His experience in these institutions has allowed him to refine his expertise in antibody development and therapeutic applications.

Collaborations

Some of his notable coworkers include Uwe Gritzan and Julian Marius Glück. Their collaborative efforts have contributed to advancing research in the field of antibody therapies.

Conclusion

Dorian Schönfeld's innovative work in antibody research, particularly regarding Semaphorin 3A, showcases his significant contributions to the scientific community. His patents reflect a commitment to advancing therapeutic solutions that could benefit various medical fields.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…